Clinical trials: Hematological Cancers
Cancer, Hematological
Pre-Exercise for Allogeneic Stem Cell Transplant Patients
The PRESENT-P study is a one-arm exercise intervention study for hematological cancer patients prior allogeneic stem cell transplantation (allo-HCT).
- Trial name
- PRESENT-P (NCT03080792)
- Testing
- Experimental: moderate to high-intensity exercise
- Where
- 5 sites in Germany
- Volunteers
- 14 people
- Sponsor
- University Hospital Heidelberg
Hematological Malignancies
A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Comparing It with 18F-FDG PET/CT Imaging
This is a prospective, open-label, single-center clinical study targeting hematological malignancies. 120 patients with a confirmed by pathology of non-Hodgkin's lymphoma or myeloma were included.
- Trial name
- NCT06834412
- Testing
- 68Ga-Pentixafor and 18F-FDG PET/CT Scan
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xijing Hospital
Hematological Malignancies, Stem Cell Transplantation
A Prospective Registry for Febrile Events in Patients With Malignant Hemopathies or Subjected to Haematopoietic Stem Cell Transplant
Hema e-chart is an electronic case record that can be changed in real time and is based on the chronological organisation of the infective events and the therapies prescribed.
- Trial name
- HEMA E-CHART (NCT01069887)
- Where
- Italy
- Volunteers
- 3,000 people
- Sponsor
- Catholic University of the Sacred Heart
Hematopoietic/Lymphoid Cancer
Supportive Care for Patients With Hematological Malignancies Undergoing Hematopoietic Cell Transplant
This pilot clinical trial studies supportive care for patients with hematological malignancies undergoing hematopoietic cell transplant. Supportive care may improve quality of life in this patient population.
- Trial name
- NCT01758484
- Testing
- palliative care, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
Hsp90 is a chemical in the body that is involved int he promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90.
- Trial name
- NCT01635712
- Testing
- SNX-5422
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Esanex Inc.
Graft-versus-Host Disease (GVHD), Hematologic Malignancies
Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophylaxis of Graft-versus-Host Disease (GVHD) in patients undergoing…
- Conditions
- Graft-versus-Host Disease (GVHD), Hematologic Malignancies, Allogeneic Stem Cell Transplantation
- Trial name
- GVHD-PTCy (NCT06926595)
- Testing
- Cyclophosphamide (primary intervention for GVHD prophylaxis)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Milton S. Hershey Medical Center
Leukemia, Acute Leukemia
Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors
The Sharing Our Strength study is being conducted to help us understand people's experiences with hematopoietic stem cell transplantation and to test a new program designed to help people recover physically and emotionally after…
- Conditions
- Leukemia, Acute Leukemia, Acute Lymphocytic Leukemia, Multiple Myeloma
- Trial name
- NCT00701844
- Testing
- Writing A (Experimental informative writing), Writing B (Experimental noninformative writing), Writing C (Control informative writing)
- Where
- 3 sites in United States
- Volunteers
- 315 people
- Sponsor
- University of North Carolina, Chapel Hill
Lymphoma, Multiple Myeloma
Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
This is a single-arm, multicenter, exploratory clinical study to evaluate the safety and efficacy of the combination of etoposide, cytarabine and PEG-rhG-CSF (EAP regimen) as first line mobilization regimen of hematopoietic stem…
- Trial name
- NCT05536154
- Testing
- Etoposide, Cytarabine, PEG-rhG-CSF
- Where
- 14 sites in China
- Volunteers
- 68 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Leukemia, Myelodysplastic Syndromes
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer
RATIONALE: Giving chemotherapy and total-body irradiation before a donor stem cell transplant or a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from…
- Trial name
- NCT00534430
- Testing
- busulfan, cyclosporine, etoposide
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Cancer, Breast Cancer
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the…
- Conditions
- Cancer, Breast Cancer, Lung Cancer, Colon Cancer
- Trial name
- LIBERATE (NCT03702309)
- Where
- Canada
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Hematological Malignancies
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
The primary goal of the study is to determine the incidence and severity of acute Graft versus Host Disease (GVHD) following human leukocyte antigen (HLA) matched related donor Hematopoetic Stem Cell(HSC) transplant in patients…
- Trial name
- NCT01246206
- Testing
- Tacrolimus and Thymoglobulin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Leukemia, Myelocytic, Acute
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
The study will compare the efficacy of the 2 treatments in intermediate and high-risk APL patients in achieving first hematological complete remission and molecular remission.
- Trial name
- NCT00962767
- Testing
- gemtuzumab ozogamicin, ATRA plus 6-MP and MTX
- Volunteers
- 168 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL)
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
This study is an open-label, controlled, multicenter, international, Phase III, randomized study of transplantation of NiCord® versus transplantation of one or two unmanipulated, unrelated cord blood units in patients with acute…
- Conditions
- Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT02730299
- Testing
- NiCord® (omidubicel), Cord Blood Unit
- Where
- 52 sites in United States, Brazil and 8 more
- Volunteers
- 125 people
- Sponsor
- Gamida Cell ltd
Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to cancer) through care…
- Conditions
- Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Multiple Chronic Conditions
- Trial name
- NCT04663100
- Testing
- Patient-reported outcome measure, Comprehensive Medication Review, Pharmacist communication
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Tennessee
Hematological Malignancies
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
This is a long-term follow-up study for participants treated with Galapagos (GLPG) CAR T-cell therapies to evaluate the long-term safety and efficacy of GLPG CAR T-cell products for 15 years post infusion.
- Trial name
- Hesperia (NCT06652633)
- Testing
- GLPG CAR T-cell therapy
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 546 people
- Sponsor
- Lakefront Biotherapeutics NV
Hematological Malignancies
Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies
The goal of this clinical research study is to learn about the effects of weighted blankets on sleep quality in patients with blood cancers. Weighted blankets are heavier blankets that contain inner weight beads.
- Trial name
- NCT06584955
- Testing
- Weighted Blanket
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoma
Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies
The purpose of this study is to find out how many irradiated natural killer (NK) cells can be safely given to patients with cancer that has recurred after an autologous stem cell transplant, and to see what effects (good and bad)…
- Conditions
- Leukemia, Lymphoma, Myeloma, Hodgkin's Disease
- Trial name
- NCT00990717
- Testing
- NK-92 cells
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University Health Network, Toronto
Solid Tumor, Sars-CoV2
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
This study is for patients that are hospitalized for Coronavirus Disease 2019 (COVID-19). The purpose of this study is to see whether neutralizing interleukin-8 (IL-8) with BMS-986253 can help improve the health condition of…
- Conditions
- Solid Tumor, Sars-CoV2, Hematological Malignancy
- Trial name
- NCT04347226
- Testing
- BMS-986253
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Columbia University
Neutropenia
The Utility of Multiplex PCR for Detection of DNA in Neutropenic Patients With Hematological Malignancies
Objectives: Invasive infections are the leading cause of morbidity and mortality in patients treated for hematological malignancies.
- Trial name
- MedIso (NCT01669005)
- Volunteers
- 84 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Hematological Malignancies Treated With Intensive Chemotherapy
Evolution of Thromboelastography During Tranexamic Acid Treatment
Patients with hematological malignancies are at increased risk of bleeding, especially during intensive chemotherapy. The aim of this study is to compare by thromboelastography changes during the intensive chemotherapy in…
- Trial name
- TTRAP-Bleeding (NCT03801122)
- Testing
- Tranexamic acid
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne